Bachem Holding AG

SWX:BANB Stok Raporu

Piyasa değeri: CHF 5.5b

Bachem Holding Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Bachem Holding kazanç ve gelirin sırasıyla yıllık 18.3% ve 18.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.3%

Kazanç büyüme oranı

18.94%

EPS büyüme oranı

Life Sciences kazanç büyümesi19.3%
Gelir büyüme oranı18.4%
Gelecekteki özkaynak getirisi15.15%
Analist kapsamı

Good

Son güncelleme06 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • Jul 30

BANB: Future Execution At New Facility Is Expected To Sustain Fair Value

Analysts have raised their price target on Bachem Holding to CHF81.40 from CHF78.80, citing model updates that reflect slightly higher assumed revenue growth and profit margins, a modestly lower discount rate, and a small adjustment to the future P/E input. What's in the News for Bachem Holding Bachem Holding announced the next phase of its greenfield project in Sisslerfeld in Eiken, Switzerland, involving a large scale production facility with a total investment of more than CHF 500 million.
Anlatı Güncellemesi • Jul 15

BANB: Rising Margin Expectations Will Increase Execution Risk And Restrain Upside

Analysts have raised their price target for Bachem Holding from CHF 46.00 to CHF 52.00, reflecting updated views that combine a slightly different discount rate, more cautious revenue growth assumptions, a higher projected profit margin, and a modestly lower future P/E multiple. What’s in the News for Bachem Holding ImmuPharma PLC appoints Bachem AG as manufacturing partner for the active pharmaceutical ingredient in its Kapiglucagon program, marking a key Chemistry, Manufacturing and Controls milestone for that project.
Analiz Makalesi • Jul 04

Does Bachem Holding (VTX:BANB) Deserve A Spot On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Anlatı Güncellemesi • Jun 22

BANB: Capacity Expansion Commitments Will Heighten Execution Risk And Restrain Upside

Analysts have raised their price target on Bachem Holding by CHF 5 to reflect updated assumptions for discount rates, growth and profitability. This move is supported by recent Street research that cites a higher target from CHF 5 at Barclays as a reference point for the new CHF level.
Anlatı Güncellemesi • Jun 05

BANB: Future Upside Will Rely On Executing Margin Assumptions And Higher P E Framework

Analysts have raised their CHF price targets on Bachem Holding, including recent CHF 5 and CHF 5 increases from two major banks, reflecting updated views on growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts are signaling a constructive view on Bachem Holding, pointing to updated price targets that reflect their latest assumptions on growth, margins, and valuation.
Anlatı Güncellemesi • May 22

BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside

Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
Anlatı Güncellemesi • May 01

BANB: Future Earnings Execution Is Expected To Support CHF 80 Upside Potential

Analysts have nudged their price target on Bachem Holding slightly higher, with recent Street research indicating a CHF 5 increase from both Barclays and Deutsche Bank to CHF 80, supported by updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts see the move to a CHF 80 target as aligned with their updated view on fair value, suggesting that current assumptions on growth and margins justify a higher valuation anchor.
Yeni Anlatı • Apr 26

Bachem Holding - The Purest Public Peptide Play?

We are living through a biological revolution. You see it on the balance sheets of the world’s largest pharmaceutical companies and you see it in the cultural zeitgeist.
Anlatı Güncellemesi • Apr 16

BANB: Future Upside Will Depend On Executing Profit Margin Assumptions

Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.
Anlatı Güncellemesi • Apr 02

BANB: Future Execution On Project Pipeline Will Support CHF 80 Upside Potential

Narrative Update Analyst price targets for Bachem Holding have shifted to a range of CHF 60 to CHF 80, with the upper end raised from CHF 75, as analysts reflect updated views on the company in their valuation work. Analyst Commentary Recent research updates on Bachem Holding point to a split in how analysts see the risk and reward around the stock, which feeds directly into the current CHF 60 to CHF 80 price target range.
Anlatı Güncellemesi • Mar 19

BANB: Future Execution On Growth Plans Will Support Higher CHF 80 Upside Potential

Analysts have nudged the consolidated price target for Bachem Holding to CHF 80, up CHF 5 from prior levels, citing updated assumptions for growth, profitability and a slightly lower P/E outlook that align with recent Street research moves. Analyst Commentary Street research on Bachem Holding has been mixed, with some analysts lifting price targets toward CHF 80 while others are more hesitant and keep targets closer to CHF 60.
Anlatı Güncellemesi • Mar 05

BANB: Future Execution On Pipeline Plans Will Support Higher Market Confidence

The updated analyst price target for Bachem Holding suggests a modest upward revision to fair value to CHF 78.66, with analysts citing slightly adjusted assumptions for the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a signal that their assumptions for Bachem Holding’s future earnings and cash flows now support a fair value above the prior level, even after revisiting discount rate and P/E inputs.
Anlatı Güncellemesi • Feb 18

BANB: Future Pipeline Execution Will Drive Upside Versus Recent Cautious Views

Analysts have adjusted their fair value estimate for Bachem Holding to CHF 76.59, reflecting updated views on growth, profitability and valuation following recent price target revisions that include a CHF 32 increase from RBC Capital and a reduction to CHF 60 from Barclays. Analyst Commentary Recent research shows a split view on Bachem Holding, with some bullish analysts lifting targets and more cautious voices trimming expectations.
Anlatı Güncellemesi • Feb 04

BANB: Higher Fair Value Will Rely On Execution Of Existing Order Book

Analysts have raised their fair value estimate for Bachem Holding from CHF 100.00 to CHF 110.00, citing updated assumptions around revenue growth, profit margins and future P/E multiples that are in line with recent Street target changes, including the higher price target from RBC and the revised level from Barclays. Analyst Commentary Recent research updates around Bachem Holding give you a mixed but useful read on how the Street is thinking about valuation and execution.
Anlatı Güncellemesi • Jan 21

BANB: Building K Execution Risks Will Limit Future Share Upside

Analysts have nudged their price target on Bachem Holding slightly lower to about CHF 60 to CHF 75, reflecting updated assumptions around discount rates, revenue growth near 21.5% and an expected future P/E close to 18.9%. They are also weighing recent research that includes a reduced CHF 60 target alongside a CHF 75 target tied to the company’s Building K expansion plans.
Anlatı Güncellemesi • Jan 07

BANB: Building K Execution Risk Will Constrain Future Upside Potential

Analysts have trimmed their average price target on Bachem Holding to CHF 60 from CHF 75, citing updated assumptions for revenue growth, profit margins and future P/E multiples that reflect a more measured outlook, even as expansion projects remain in focus. Analyst Commentary Recent street research on Bachem highlights a mix of views, with some analysts seeing potential tied to expansion projects such as Building K, while others are recalibrating expectations and price targets to reflect what they view as a more balanced risk and reward profile.
Anlatı Güncellemesi • Dec 14

BANB Building K Expansion Will Define Future Upside And Execution Risk

Analysts have raised their price target for Bachem Holding from approximately CHF 58 to about CHF 75, citing increased confidence in revenue growth driven by the company's Building K expansion project, despite a slightly higher discount rate and modestly lower profit margin and valuation multiples. Analyst Commentary Recent research commentary highlights a more constructive stance on Bachem Holding, with the upgraded price target to CHF 75 framed around the growth potential from the Building K expansion project.
Analiz Makalesi • Dec 01

At CHF51.85, Is Bachem Holding AG (VTX:BANB) Worth Looking At Closely?

While Bachem Holding AG ( VTX:BANB ) might not have the largest market cap around , it received a lot of attention from...
Analiz Makalesi • Oct 25

Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings

Bachem Holding AG's ( VTX:BANB ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right...
Anlatı Güncellemesi • Sep 26

Building K Production Will Serve Peptide And Oligonucleotide Therapies

Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.
Analiz Makalesi • Sep 18

Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analiz Makalesi • Aug 16

Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly

SWX:BANB 1 Year Share Price vs Fair Value Explore Bachem Holding's Fair Values from the Community and select yours Some...
User avatar
Yeni Anlatı • Mar 02

Building K And 24-Hour Operations Will Improve Efficiency

Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.

Kazanç ve Gelir Büyüme Tahminleri

SWX:BANB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CHF Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20281,377263-1003139
12/31/20271,166229-1592469
12/31/2026942177-2401649
6/30/2026709149-58290N/A
3/31/2026702149-58281N/A
12/31/2025695149-58272N/A
9/30/2025687141-95208N/A
6/30/2025678134-133144N/A
3/31/2025642127-136145N/A
12/31/2024605120-138146N/A
9/30/2024592117-96195N/A
6/30/2024578114-53244N/A
3/31/2024578113-36247N/A
12/31/2023577112-19250N/A
9/30/2023557105-40193N/A
6/30/202353799-62137N/A
3/31/2023534100-56115N/A
12/31/2022532101-5093N/A
9/30/202251599-4791N/A
6/30/202249998-4488N/A
3/31/2022501106-3293N/A
12/31/2021503115-1998N/A
9/30/20214841071107N/A
6/30/20214649821116N/A
3/31/20214338834116N/A
12/31/20204027846115N/A
9/30/20203797247103N/A
6/30/2020356674791N/A
3/31/202033560N/A78N/A
12/31/201931454N/A64N/A
9/30/201931052N/A60N/A
6/30/201930651N/A57N/A
3/31/201929449N/A41N/A
12/31/201828347N/A26N/A
9/30/201826845N/A24N/A
6/30/201825342N/A23N/A
3/31/201825742N/A30N/A
12/31/201726242N/A36N/A
9/30/201725241N/A36N/A
6/30/201724240N/A35N/A
3/31/201723941N/A38N/A
12/31/201623641N/A40N/A
9/30/201622939N/A46N/A
6/30/201622236N/A52N/A
3/31/201621634N/A57N/A
12/31/201520932N/A61N/A
9/30/201520331N/A59N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BANB 'nin tahmini kazanç büyümesi (yıllık 18.3% ) tasarruf oranının ( 0.6% ) üzerindedir.

Kazançlar ve Piyasa: BANB şirketinin kazançlarının (yıllık 18.3% ) Swiss pazarından (yıllık 12.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BANB şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: BANB şirketinin gelirinin (yıllık 18.4% ) Swiss pazarından (yıllık 5.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BANB şirketinin gelirinin (yıllık 18.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BANB 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.1 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/06 22:06
Gün Sonu Hisse Fiyatı2026/08/06 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Bachem Holding AG 17 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Charles PitmanBarclays
Estelle BétriseyBerenberg
Patrick LaagerBerenberg